SARS-CoV-2 vaccination improves HBV seroconversion rate through heterological immunity

Kidney Int. 2023 Jan;103(1):223-225. doi: 10.1016/j.kint.2022.10.012. Epub 2022 Nov 1.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Hepatitis B virus
  • Humans
  • SARS-CoV-2
  • Seroconversion
  • Vaccination

Substances

  • COVID-19 Vaccines
  • Antibodies, Viral